^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastrointestinal Cancer

    1d
    CODAP: Evaluation of the Clinical Impact of the Numerique Medical Device MAELA® Ont the Care Pathway in Digestive Oncology Surgery (clinicaltrials.gov)
    P=N/A, N=555, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New trial
    1d
    New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool (clinicaltrials.gov)
    P=N/A, N=246, Terminated, Poitiers University Hospital | N=1100 --> 246 | Trial completion date: Feb 2024 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Feb 2024 --> Oct 2025; The study was stopped due to recruitment difficulties
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Head-to-Head
    |
    MSH2 (MutS Homolog 2)
    1d
    Sarcopenia and Neuromuscular Block in Gastrointestinal Cancer Surgery (clinicaltrials.gov)
    P=N/A, N=100, Completed, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital | Recruiting --> Completed
    Trial completion
    1d
    CHEMOVES: Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
    New trial
    2d
    Role of magnolol in gastrointestinal cancers: Recent trends and future perspectives. (PubMed, Semin Oncol)
    In addition, challenges related to magnolol's poor aqueous solubility, rapid metabolism, and limited bioavailability are discussed, with particular focus on nanotechnology-based delivery systems developed to improve its pharmacokinetic profile and therapeutic performance. This current review provides an integrated overview of magnolol's molecular mechanisms, chemical optimization strategies, and translational limitations in gastrointestinal cancer therapy, and outlines future research directions necessary to support its progression toward clinical application.
    Review • Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    2d
    A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers (clinicaltrials.gov)
    P1, N=80, Recruiting, Janssen Research & Development, LLC | N=35 --> 80
    Enrollment change
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    3d
    Frailty in Patients With Gastrointestinal Cancer Who Are Undergoing Major Surgery (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, The Guthrie Clinic | Active, not recruiting --> Recruiting
    Enrollment open
    3d
    Case Report: A liver metastasis 24 years after resection of a very low-risk jejunal gastrointestinal stromal tumor. (PubMed, Front Oncol)
    Adjuvant imatinib (400 mg/day) was initiated, with no recurrence at 18-month follow-up...It underscores the need for lifelong vigilance, even in low-risk patients, and emphasizes the critical roles of advanced imaging, immunohistochemistry, and molecular diagnostics in diagnosing late metastases. Individualized follow-up strategies and consideration of long-term surveillance for selected low-risk GISTs warrant reevaluation in the era of molecular-targeted therapy.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • ANO1 (Anoctamin 1)
    |
    PDGFRA mutation
    |
    imatinib
    3d
    Enhanced mRNA Expression of Colonic IL-6 in Cronkhite-Canada Syndrome Bearing Colorectal Cancer. (PubMed, In Vivo)
    IL-6-mediated inflammation-associated carcinogenesis might be involved in the transformation of CCS-associated polyps into CRC.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    3d
    BOLSTER: Learning New Skills to Thrive (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Feb 2028 --> Sep 2029 | Trial primary completion date: Nov 2027 --> Sep 2028
    Trial completion date • Trial primary completion date
    3d
    FUSION: Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastrointestinal Cancers (clinicaltrials.gov)
    P=N/A, N=198, Completed, Ankara Etlik City Hospital | Recruiting --> Completed | N=82 --> 198
    Trial completion • Enrollment change
    |
    5-fluorouracil
    3d
    A Randomized, Double-blind, Placebo-controlled, Prospective, Multi-center Trial Evaluating the Improvement of Nutritional Status and Sarcopenia With Silkworm Pupa Tablets in Patients With Malignancies (clinicaltrials.gov)
    P3, N=480, Not yet recruiting, First Affiliated Hospital of Zhejiang University
    New P3 trial